FST

Across TCGA pan-cancer cohorts, FST mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FST data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FST mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FST expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, HNSC, and UCEC are the cancer types where FST mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.256	0.893	<.001	62	view →
HNSC	OS	Tertile	IV	0.933	0.549	<.001	32	view →
UCEC	OS	Tertile	II,III,IV	0.159	1.000	.038	24	view →
LUAD	OS	Median	II,III,IV	0.268	0.851	.001	18	view →
LSCC	DFS	Quartile	III,IV	1.000	0.433	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FST–PDAC (DFS)

Open the PDAC breakdown →